

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-17. Canceled

18. (Currently Amended) The method for treating schizophrenia of claim 34
~~pharmaceutical composition according to claim 15~~, wherein the St. John's wort extract
comprises the following components in weight percent : 0.01 to = 2% hypericins
~~hypericins~~, 0.01 to = 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40%
hypericins and 1 to = 6% hyperforins.

19. Cancelled.

20. (Currently Amended) The method for treating schizophrenia of claim 34 ~~The~~
~~pharmaceutical composition according to claim 15~~, wherein the saffron extract
comprises the following components in weight percent: α -~~;~~ and β -pinene, 1,8-cineol ~~+~~,
~~8-cineol~~, crocin, and picrocrocin , and wherein the saffron extract optionally further
comprises safranal (a degradation product of picrocrocin) ~~as well as optionally the~~
~~degradation product thereof safranal~~, particularly preferred in the following
concentrations by weight: 5 to = 10% pinene and cineol, 4 to = 10% picrocrocin and/or 2
to = 6% safranal.

21. (Currently Amended) The method for treating schizophrenia of claim 34 ~~The pharmaceutical composition according to claim 15~~, wherein the ginseng root extract comprises the components by weight, *inter alia*, triterpene saponins ~~saponines~~ (ginsenosides/ginsenoids), sesquiterpenes and polyacetylenes, particularly preferred in the following concentrations: 3 to = 9% ginsenoids.

22. (Currently Amended) The method for treating schizophrenia of claim 34 ~~The pharmaceutical composition according to claim 14~~, wherein said pharmaceutical composition is in the form of a liquid, a semi-solid a solid_, such as a solution, a suspension, a tablet, a capsule, an effervescent tablet, an effervescent granulate, a chewable tablet or a suppository.

23. (Currently Amended) The method for treating schizophrenia of claim 34 ~~The pharmaceutical composition according to claim 15~~, wherein said pharmaceutical composition contains 300 to 2700, preferably 750 to = 1500 mg of St. John's wort extract.

24. (Currently Amended) The method for treating schizophrenia of claim 34 ~~The pharmaceutical composition according to claim 15~~, wherein said pharmaceutical composition contains 50 mg to = 1000 mg of at least one extract selected from the group consisting of gingko biloba, Crocis sativus ~~Crocis sativus~~ and Panax ginseng ~~Panax ginseng~~.

25. (Currently Amended) The method for treating schizophrenia of claim 34,
wherein the A pharmaceutical composition in the form of a suspension, a dragee, an
effervescent tablet, an effervescent granulate, a chewable tablet or a suppository
containing at least one of St. John's wort, ginkgo biloba, saffron and/or *Panax ginseng*
extract ~~Panax ginseng~~ in addition to, as further components, a psychotherapeutic drug
for the simultaneous, separate or graduated treatment of schizophrenia.

Claims 26-29. (Cancelled).

30. (Currently Amended) The method for treating schizophrenia of claim 34, Use
according to claim 16, wherein the St. John's wort extract comprises the following
components by weight percent: 0.01 - 2% hypericins, 0.01 - 30% hypericins, 2 to -
35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 to - 6% hyperforins.

Claims 31-33. (Cancelled).

34. (Currently Amended) A method for treating schizophrenia, said method
comprising administering a therapeutically effective amount of a the pharmaceutical
composition of Claim 14 comprising:

at least one medicament comprising at least one extract selected from the group
consisting of an extract of *Hypericum perforatum* (St. John's wort), an extract of *Crocus*

sativus (saffron) and an extract of *Panax ginseng* (ginseng); and
a pharmaceutically acceptable carrier.

35. (Currently Presented) The method for treating schizophrenia of Claim 34, wherein the pharmaceutical composition is administered in combination with at least one drug for treating schizophrenia.

36. (Currently Amended) The method for treating schizophrenia of Claim ~~34~~, ~~35~~ wherein, ~~the method for treating schizophrenia of Claim 14~~ wherein the pharmaceutical composition is administered in combination with at least one psychotherapeutic drug for treating neuroleptics.

37. (Currently Amended) The method for treating schizophrenia of Claim 36 wherein, the drug for treating neuroleptics is—selected from the group consisting of haloperidol, benperidol, chloroprotixene, flupentixol, fluphenazine, perazine, perphenazine, thioridazine, atypical neuroletics,—clozapine, olanzapine, seroquel, sertindole, and combinations thereof.

38. (Currently Amended) The A method for treating schizophrenia of claim 34, wherein, a therapeutically effective amount of the pharmaceutical composition ~~of Claim 23~~ is administered up to 3 times per day.

39. (Currently Amended) The A method for treating schizophrenia of claim 34,
said method comprising administering the pharmaceutical composition with a of Claim
~~24~~ wherein the daily dose of the extracts of is 50 mg to - 1000 mg in the case of *Crocus*
sativus and *Panax ginseng* and 300 to 2700 mg in the case of *Hypericum perforatum*.

Claims 40-41 (Cancelled).